Global Blood Culture Test Market, By Method (Conventional/Manual Methods and Automated Methods), Product (Consumables, Instruments and Software and Services), Technology (Culture-Based Technology, Molecular Technologies and Proteomics Technology), Application (Bacteraemia, Fungaemia and Mycobacterial Detection), End-User (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other Laboratories) - Industry Trends and Forecast to 2030.
Blood Culture Test Market Analysis and Size
Rising prevalence of sepsis and other blood related infections is a root cause for the rise in blood culture test market value. Growing approval rate of new products, such as instruments and consumables for Bloodstream Infections (BSI) diagnosis will further create lucrative and remunerative opportunities for the Blood culture test market.
Data Bridge Market Research analyses that the blood culture test market which was USD 4,900.00 million in 2022, is expected to reach USD 8,400.00 million by 2030, and is expected to undergo a CAGR of 6.0% during the forecast period of 2023 to 2030. “Automated Methods” dominates the method segment of the blood culture test market owing to the increasing prevalence of bloodstream infections. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Blood Culture Test Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Method (Conventional/Manual Methods and Automated Methods), Product (Consumables, Instruments and Software and Services), Technology (Culture-Based Technology, Molecular Technologies and Proteomics Technology), Application (Bacteraemia, Fungaemia and Mycobacterial Detection), End User (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories and Other Laboratories)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
BD (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Eli Lilly and Company (U.S.) Terumo Corporation (Japan), Bruker Corporation ( U.S.), bioMérieux SA (France), Bayer AG (Germany), Merck & Co., Inc. (U.S.), Thermo Fisher Scientific Inc., (U.S.), Siemens Healthcare GmbH: (Germany), Danaher Corporation (U.S.), ZenTech S.A. (Belgium), ZeptoMetrix Corporation (U.S.), BioFire Diagnostics (a subsidiary of bioMérieux) (U.S.), CytoTest Inc. (U.S.), Mikroscan Technologies, Inc. (U.S), Leica Biosystems Nussloch GmbH (a subsidiary of Danaher) (Germany), Devyser (Sweden)
|
|
Market Opportunities
|
|
Market Definition
Blood culture test are undergone to detect the presence of any microorganisms such as bacteria or fungi in the blood. Presence of bacteria, fungi or yeast in the blood will result in blood infection and give birth to many diseases. Blood culture test are used to determine the presence of infection, causative agents and to further help to healthcare provider in deciding the course of treatment.
Global Blood Culture Test Market Dynamics
Drivers
- Increasing Prevalence of Bloodstream Infections
The rising incidence of bloodstream infections, including sepsis, is a major driver for the blood culture market. Blood culture test are vital for accurate diagnosis, appropriate treatment, and improved patient outcomes.
- Growing Awareness and Initiatives for Infection Control
There is a heightened focus on infection control measures in healthcare settings, leading to increased adoption of Blood culture test. Efforts to prevent healthcare-associated infections and implement surveillance programs drive the demand for blood culture solutions.
Opportunity
- Adoption of Molecular Diagnostic Techniques
The adoption of molecular diagnostic techniques, such as polymerase chain reaction (PCR) and nucleic acid amplification, in blood culture testing presents opportunities for faster and more accurate pathogen detection.
Restraint/Challenge
- Lack of Skilled Professionals
Adequate training and expertise are required for performing and interpreting Blood culture test accurately. The shortage of skilled laboratory professionals can be a restraint, particularly in certain regions, affecting the widespread implementation of blood culture testing.
This blood culture test market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blood culture test market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2021, F. Hoffmann-La Roche Ltd acquired GenMark Diagnostics to expand its molecular diagnostics portfolio with GenMark’s expertise in syndromic testing. GenMark's ePlex systems enhance Roche's work in managing infectious diseases and antibiotic resistance. The ePlex platform is designed to detect multiple pathogens from a single rapid test and a patient sample, allowing clinicians to determine the cause of infection and prescribe treatment within hours. Panther Healthcare launched the Smart Powered Stapler platform, which provides intelligent and automated control of tissue fixation, transection and resection across gastrointestinal (including bariatric), thoracic, colorectal, oncology, gynecology and other open and laparoscopic surgical procedures. The device was released in Europe, the Middle East, Africa, Asia and Latin America
Global Blood Culture Test Market Scope
The blood culture test market is segmented on the basis of method, product, technology, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Method
- Conventional/Manual Methods
- Automated Methods
Product
- Consumables
- Instruments
- Software and Services
Technology
- Culture-Based Technology
- Molecular Technologies
- Proteomics Technology
Application
- Bacteraemia
- Fungaemia
- Mycobacterial Detection
End-User
- Hospital Laboratories
- Reference Laboratories
- Academic Research Laboratories
- Other
Global Blood Culture Test Market Regional Analysis/Insights
The blood culture test market is analysed and market size insights and trends are provided by country, method, product, technology, application and end user as referenced above.
The countries covered in the blood culture test market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
North America dominates the market and will continue to during the forecast period. This is because of the prevalence of a favourable reimbursement scenario and occurrence of major key players.
Asia-Pacific on the other hand is set to project the highest CAGR for the forecast period. This is because of the rising expenditure of healthcare infrastructure, rising investments for research and development activities and increasing prevalence of various blood related infections.
The country s section of the blood culture test market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Blood Culture Test Market Share Analysis
The blood culture test market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to blood culture test market.
Some of the major players operating in the blood culture test market are:
- BD (U.S.)
- Abbott Laboratories (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Eli Lilly and Company (U.S.)
- Terumo Corporation (Japan)
- Bruker Corporation (U.S.)
- bioMérieux SA (France)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Siemens Healthcare GmbH (Germany)
- Danaher Corporation (U.S.)
- ZenTech S.A. (Belgium)
- ZeptoMetrix Corporation (U.S.)
- BioFire Diagnostics (a subsidiary of bioMérieux) (U.S.)
- CytoTest Inc. (U.S.)
- Mikroscan Technologies, Inc. (U.S.)
- Leica Biosystems Nussloch GmbH (a subsidiary of Danaher) (Germany)
- Devyser (Sweden)
SKU-